Enovis (ENOV)
Market Price (4/23/2026): $23.74 | Market Cap: $1.4 BilSector: Health Care | Industry: Health Care Equipment
Enovis (ENOV)
Market Price (4/23/2026): $23.74Market Cap: $1.4 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, Precision Medicine, and Digital Health & Telemedicine. Themes include Geriatric Care, Show more. | Weak multi-year price returns2Y Excs Rtn is -100%, 3Y Excs Rtn is -129% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -19 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -0.8% Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 99% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -91% Key risksENOV key risks include [1] significant goodwill impairment charges and acquisition integration hurdles, Show more. |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, Precision Medicine, and Digital Health & Telemedicine. Themes include Geriatric Care, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -100%, 3Y Excs Rtn is -129% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -19 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -0.8% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 99% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -91% |
| Key risksENOV key risks include [1] significant goodwill impairment charges and acquisition integration hurdles, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Enovis (ENOV) stock has lost about 10% since 12/31/2025 because of the following key factors:
1. Enovis reported a substantial non-cash goodwill impairment charge for Q4 and full-year 2025.
The company announced a Q4 2025 net loss from continuing operations of $519 million, which included a significant non-cash goodwill impairment charge of $501 million. For the full year 2025, the net loss from continuing operations reached $1.18 billion, with total goodwill impairment charges of $1.05 billion. This impairment suggests a reevaluation of the value of previous acquisitions, signaling potential concerns about future asset performance and significantly impacting investor sentiment.
2. The company missed revenue expectations in its Q4 2025 earnings report.
While Enovis's adjusted earnings per share (EPS) of $0.95 beat analyst estimates, its quarterly revenue of $575.76 million fell short of the consensus expectation of $584.30 million. This revenue miss, despite an EPS beat, likely contributed to a negative market reaction, indicating slower-than-anticipated top-line growth.
Show more
1. Enovis reported a substantial non-cash goodwill impairment charge for Q4 and full-year 2025.
The company announced a Q4 2025 net loss from continuing operations of $519 million, which included a significant non-cash goodwill impairment charge of $501 million. For the full year 2025, the net loss from continuing operations reached $1.18 billion, with total goodwill impairment charges of $1.05 billion. This impairment suggests a reevaluation of the value of previous acquisitions, signaling potential concerns about future asset performance and significantly impacting investor sentiment.
2. The company missed revenue expectations in its Q4 2025 earnings report.
While Enovis's adjusted earnings per share (EPS) of $0.95 beat analyst estimates, its quarterly revenue of $575.76 million fell short of the consensus expectation of $584.30 million. This revenue miss, despite an EPS beat, likely contributed to a negative market reaction, indicating slower-than-anticipated top-line growth.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -10.8% change in ENOV stock from 12/31/2025 to 4/22/2026 was primarily driven by a -11.4% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 26.64 | 23.76 | -10.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,233 | 2,248 | 0.7% |
| P/S Multiple | 0.7 | 0.6 | -11.4% |
| Shares Outstanding (Mil) | 57 | 57 | 0.0% |
| Cumulative Contribution | -10.8% |
Market Drivers
12/31/2025 to 4/22/2026| Return | Correlation | |
|---|---|---|
| ENOV | -10.8% | |
| Market (SPY) | -5.4% | 30.4% |
| Sector (XLV) | -5.4% | 41.5% |
Fundamental Drivers
The -21.7% change in ENOV stock from 9/30/2025 to 4/22/2026 was primarily driven by a -23.7% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 30.34 | 23.76 | -21.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,190 | 2,248 | 2.7% |
| P/S Multiple | 0.8 | 0.6 | -23.7% |
| Shares Outstanding (Mil) | 57 | 57 | -0.1% |
| Cumulative Contribution | -21.7% |
Market Drivers
9/30/2025 to 4/22/2026| Return | Correlation | |
|---|---|---|
| ENOV | -21.7% | |
| Market (SPY) | -2.9% | 39.1% |
| Sector (XLV) | 5.6% | 43.6% |
Fundamental Drivers
The -37.8% change in ENOV stock from 3/31/2025 to 4/22/2026 was primarily driven by a -40.4% change in the company's P/S Multiple.| (LTM values as of) | 3312025 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 38.21 | 23.76 | -37.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,108 | 2,248 | 6.7% |
| P/S Multiple | 1.0 | 0.6 | -40.4% |
| Shares Outstanding (Mil) | 56 | 57 | -2.2% |
| Cumulative Contribution | -37.8% |
Market Drivers
3/31/2025 to 4/22/2026| Return | Correlation | |
|---|---|---|
| ENOV | -37.8% | |
| Market (SPY) | 16.3% | 48.8% |
| Sector (XLV) | 1.6% | 44.8% |
Fundamental Drivers
The -55.6% change in ENOV stock from 3/31/2023 to 4/22/2026 was primarily driven by a -67.4% change in the company's P/S Multiple.| (LTM values as of) | 3312023 | 4222026 | Change |
|---|---|---|---|
| Stock Price ($) | 53.49 | 23.76 | -55.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,563 | 2,248 | 43.8% |
| P/S Multiple | 1.9 | 0.6 | -67.4% |
| Shares Outstanding (Mil) | 54 | 57 | -5.2% |
| Cumulative Contribution | -55.6% |
Market Drivers
3/31/2023 to 4/22/2026| Return | Correlation | |
|---|---|---|
| ENOV | -55.6% | |
| Market (SPY) | 63.3% | 49.2% |
| Sector (XLV) | 18.4% | 43.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ENOV Return | 20% | 16% | 5% | -22% | -39% | -11% | -38% |
| Peers Return | 1% | -3% | -1% | 12% | 12% | 0% | 21% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 3% | 88% |
Monthly Win Rates [3] | |||||||
| ENOV Win Rate | 50% | 42% | 42% | 42% | 33% | 50% | |
| Peers Win Rate | 52% | 55% | 48% | 50% | 52% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| ENOV Max Drawdown | -3% | -22% | -18% | -31% | -41% | -19% | |
| Peers Max Drawdown | -11% | -21% | -17% | -7% | -12% | -6% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: SYK, ZBH, JNJ, GMED, MDT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/22/2026 (YTD)
How Low Can It Go
| Event | ENOV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -38.0% | -25.4% |
| % Gain to Breakeven | 61.4% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -62.4% | -33.9% |
| % Gain to Breakeven | 165.7% | 51.3% |
| Time to Breakeven | 294 days | 148 days |
| 2018 Correction | ||
| % Loss | -55.5% | -19.8% |
| % Gain to Breakeven | 124.8% | 24.7% |
| Time to Breakeven | 788 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -80.4% | -56.8% |
| % Gain to Breakeven | 410.5% | 131.3% |
| Time to Breakeven | 875 days | 1,480 days |
Compare to SYK, ZBH, JNJ, GMED, MDT
In The Past
Enovis's stock fell -38.0% during the 2022 Inflation Shock from a high on 4/20/2022. A -38.0% loss requires a 61.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Enovis (ENOV)
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
AI Analysis | Feedback
It's like a Zimmer Biomet or Stryker, but also offering all the orthopedic braces and physical therapy devices.
A more focused Johnson & Johnson, specializing in all things musculoskeletal — from joint implants to braces and recovery tools.
AI Analysis | Feedback
```html- Orthopedic Bracings: Rigid and soft medical devices designed to support, protect, or immobilize parts of the body.
- Therapy Products: Includes hot and cold therapy products for pain relief and recovery, and electrical stimulators for pain management.
- Bone Growth Stimulators: Devices that aid in the healing and growth of bone.
- Vascular Therapy Systems and Compression Garments: Products aimed at improving circulation and managing swelling.
- Therapeutic Footwear: Special shoes and inserts designed to provide support, comfort, and aid in the treatment of foot conditions.
- Reconstructive Joint Products: Surgical implants and devices for the reconstruction or replacement of joints such as the hip, knee, shoulder, elbow, foot, ankle, and finger.
- Physical Therapy Products: A range of products utilized by professionals during physical rehabilitation.
AI Analysis | Feedback
Enovis Corporation (ENOV) sells its medical technology products primarily to other companies and professional entities rather than directly to individual consumers. While specific names of major customer companies are not disclosed in the provided information, based on the company description, its major customers include the following categories:
- Independent Distributors: These are companies that procure medical devices from Enovis and distribute them further to various points of sale or healthcare providers.
- Consumer Retail Stores: These include various retail businesses, such as general consumer retail chains, sporting goods stores, or specialized medical supply stores, that purchase Enovis products to sell directly to end-consumers.
- Pharmacies: This category encompasses both large pharmacy chains and independent pharmacies that stock and sell Enovis's non-prescription medical devices and health products.
- Healthcare Facilities and Professional Practices: Enovis sells directly to clinics, hospitals, and the practices of healthcare professionals such as orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, and athletic trainers, who use these products for patient treatment.
AI Analysis | Feedback
nullAI Analysis | Feedback
Damien McDonald Chief Executive Officer
Damien McDonald joined Enovis as CEO on May 12, 2025. He has over 35 years of experience in the medical device industry. Prior to Enovis, he served as CEO of LivaNova, a global medical technology company, for six years, where he improved growth, profitability, and shareholder value. Earlier in his career, he held leadership positions as a Group Executive and Corporate Vice President for a $1.5 billion group of dental consumables companies at Danaher, and also led Zimmer's spine division and global marketing for Johnson & Johnson's Ethicon business unit.
Ben Berry Chief Financial Officer
Phillip “Ben” Berry is Senior Vice President and Chief Financial Officer of Enovis, a role he has held since January 1, 2023, having joined the company in 2020 to lead finance for its medical technology segment. He has played a key role in strengthening financial teams and processes, contributing to improved operating performance and profit margins, and shaping growth strategy, including acquisitions. Previously, he spent 18 years in the medical technologies sector with Alcon, including its launch as an independent public company, serving in various finance leadership roles focused on strategy, operations, and business process improvement.
Patricia Lang Senior Vice President and Chief Human Resources Officer
Patricia Lang brings over 25 years of experience in human resources and related fields, with significant expertise in the diligence, acquisition, and integration of complex multicultural companies. Before joining Enovis, she served as the Chief People Officer for Diebold Nixdorf. Her background also includes human resources and operations leadership positions at companies such as Mylan Pharmaceuticals, CONSOL Energy, Mercer Consulting, and Cigna.
Bradley J. Tandy Senior Vice President and Chief Legal Officer
Bradley J. Tandy has served as Senior Vice President and Chief Legal Officer of Enovis since 2019. Prior to this, he was Executive Vice President, General Counsel, and Secretary of DJO Global. His career also includes multiple senior legal roles at Biomet, Inc. from 1992 to 2014, culminating as Senior Vice President, General Counsel, and Secretary. He began his career as a partner in a law firm specializing in medical device and healthcare clients and also served 22 years as an elected public official in Kosciusko County, Indiana.
Oliver Engert Chief Administrative Officer
Oliver Engert was appointed Chief Administrative Officer of Enovis, effective January 5, 2026. In this newly created role, he is responsible for leading strategy development, driving organizational efficiency, and enhancing operational excellence. He brings 30 years of experience from McKinsey & Company, where he most recently served as Senior Partner Emeritus, Special Advisor, supporting companies with strategy, transformations, mergers and acquisitions, organization design, and performance improvement.
AI Analysis | Feedback
Here are the key risks to Enovis's business:Key Risks to Enovis (ENOV)
- Acquisition and Integration Risks, including Goodwill Impairment: Enovis's growth strategy relies significantly on acquisitions, which inherently carries risks related to successful integration, potential loss of key personnel, and unanticipated expenses. The company has faced substantial non-cash goodwill impairment charges in recent years, indicating that acquired assets may not be generating expected returns or that market conditions have deteriorated. These impairments directly impact net income and can raise concerns about capital allocation and the long-term value of acquired businesses.
- Regulatory and Reimbursement Risks: As a medical technology company, Enovis operates within a highly regulated environment. Changes in healthcare laws, government regulations, or reimbursement policies could adversely affect the demand for its medical device products and its financial performance. Failure to obtain necessary regulatory approvals for new products or non-compliance with existing regulations could also hinder its ability to market products.
- Supply Chain and Global Economic Risks: Enovis is exposed to risks related to its global supply chain, including potential shortages of raw materials and components, as well as price fluctuations. Furthermore, broader global economic conditions, such as geopolitical tensions, inflation, and foreign currency exchange rate fluctuations, can disrupt operations, increase costs, and negatively impact the company's financial results and stability.
AI Analysis | Feedback
The emergence of advanced regenerative medicine and biological therapies that can repair or regrow damaged musculoskeletal tissues and joints, potentially reducing or eliminating the need for reconstructive joint surgery and traditional orthopedic devices offered by Enovis.AI Analysis | Feedback
Enovis Corporation operates in several medical technology markets, with the following addressable market sizes for its main products and services:
- Orthopedic Braces and Supports: The global orthopedic braces and supports market was valued at approximately USD 4.57 billion in 2025 and is projected to grow to about USD 9.07 billion by 2035. North America held the largest market share, accounting for 42% in 2025. The U.S. orthopedic braces market alone was valued at USD 1.39 billion in 2025 and is projected to reach USD 2.12 billion by 2033.
- Bone Growth Stimulators: The global bone growth stimulator market was valued at USD 1.186.12 million in 2025 and is projected to reach USD 2,021.13 million by 2032. North America is the dominant region in this market, holding a 41.09% share in 2025. The U.S. bone growth stimulator market was valued at USD 0.66 billion in 2024 and is expected to reach USD 0.99 billion by 2032.
- Reconstructive Joint Products: The global joint reconstruction devices market was valued at USD 28.91 billion in 2024 and is expected to reach USD 41.23 billion by 2033. North America held the largest global revenue share of 46.48% in 2024. In the U.S., the joint reconstruction devices market was valued at USD 12.54 billion in 2024 and reached USD 13.00 billion in 2025.
- Physiotherapy Equipment: The global physiotherapy equipment market is projected to reach USD 9.45 billion by 2029, growing from USD 6.70 billion in 2024. North America held the largest market share in 2023.
AI Analysis | Feedback
Here are the 3-5 expected drivers of future revenue growth for Enovis (ENOV) over the next 2-3 years:-
New Product Innovation and Portfolio Expansion
Enovis is prioritizing a robust innovation pipeline and a multi-year cadence of high-impact product launches to drive future revenue growth. The company reported a significant increase in 510(k) clearances in 2025, indicating an acceleration in its product development efforts. New systems such as the Augmented Reverse Glenoid (ARG) for shoulders and the Nebula hip stem are already contributing to above-market growth in the Reconstruction segment, with the upcoming launch of the Manafuse LIPUS ultrasound technology expected to further contribute. Enovis's management emphasizes advancing its rich innovation pipeline and successful product introductions, including offerings like ARVIS and OrthoDrive Impactor, to support steady organic growth. -
Sustained Organic Growth in the Reconstruction Segment, Fueled by the LimaCorporate Integration
The Reconstruction (Recon) segment is identified as a primary growth leader for Enovis. The company's Recon segment outperformed the market with 8% organic growth in 2025, and management projects high single-digit growth for this segment in 2026. This growth is significantly driven by the integration of LimaCorporate S.p.A., an acquisition that has expanded Enovis's global footprint and complementary product portfolio, particularly in the fast-growing extremities market. Enovis aims to realize over $40 million in cost and revenue synergies from the Lima integration within three years, directly boosting the Recon segment's revenue performance. -
Continued Commercial Execution and Overall Organic Growth
Enovis expects to achieve mid-single-digit organic revenue growth of 4% to 6% year-over-year for 2026, building on a 6% organic growth rate in 2025. This growth is supported by a focus on disciplined commercial execution across its product portfolio. The company's strategic focus on operational excellence and capitalizing on market opportunities is intended to sustain this organic growth. Management consistently highlights continued commercial execution as a key priority to position Enovis for durable, profitable growth.
AI Analysis | Feedback
Capital Allocation Decisions for Enovis (ENOV) Over the Last 3-5 Years
Share Repurchases
- Enovis made minimal share repurchases in 2021, with $971,000 in March and $32,000 in June.
- As of April 1, 2022, a $100 million share repurchase authorization from 2018 remained, but no repurchases had been made under this plan since the third quarter of 2018.
Share Issuance
- Enovis's shares outstanding increased from 39.498 million at the end of 2020 to 57.195 million at the end of 2025, indicating share issuance over this period.
- In Q2 2025, Enovis reported net proceeds from the issuance of common stock of $1.129 million and $1.177 million.
Outbound Investments
- In September 2023, Enovis acquired Italian-based LimaCorporate S.p.a. for EUR 800 million, an acquisition anticipated to boost sales by approximately $300 million.
- Enovis divested its Dr. Comfort diabetic shoe business in October 2025 for cash proceeds of up to $60 million, including an upfront payment of $45 million. This divestiture was expected to reduce full-year 2025 revenue guidance by about $15 million.
Capital Expenditures
- Enovis's capital expenditures were $97 million in 2021, $103 million in 2022, $90 million in 2023, $181 million in 2024, and $197 million in 2025.
- For 2026, capital expenditures are expected to involve substantial investments aimed at integrating LimaCorporate and fueling growth.
- The company expects free cash flow conversion to be 25% or more of adjusted net income in 2026, supporting these investments.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Enovis Earnings Notes | 12/16/2025 | |
| Why Enovis Stock Moved: ENOV Stock Has Lost 51% Since 2023 Fiscal End, Primarily Due To Unfavorable Change In Price To Sales Multiple (P/S) | 08/08/2025 | |
| ENOV Dip Buy Analysis | 07/10/2025 | |
| Enovis (ENOV) Valuation Ratios Comparison | 05/15/2025 | |
| Enovis Total Shareholder Return (TSR): -21.7% in 2024 and -1.5% 3-yr compounded annual returns (above peer average) | 03/07/2025 | |
| Time To Buy Enovis Stock? | 02/28/2025 | |
| Enovis (ENOV) Operating Cash Flow Comparison | 02/17/2025 | |
| Enovis (ENOV) Net Income Comparison | 02/15/2025 | |
| Enovis (ENOV) Operating Income Comparison | 02/14/2025 | |
| ARTICLES | ||
| Stocks Trading At 52-Week Low | 01/24/2026 |
Trade Ideas
Select ideas related to ENOV.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
| 08312021 | ENOV | Enovis | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | -18.6% | 5.1% | -25.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 94.02 |
| Mkt Cap | 62.5 |
| Rev LTM | 16,674 |
| Op Inc LTM | 3,208 |
| FCF LTM | 2,852 |
| FCF 3Y Avg | 2,443 |
| CFO LTM | 3,371 |
| CFO 3Y Avg | 2,963 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.0% |
| Rev Chg 3Y Avg | 8.3% |
| Rev Chg Q | 10.0% |
| QoQ Delta Rev Chg LTM | 2.5% |
| Op Inc Chg LTM | 15.8% |
| Op Inc Chg 3Y Avg | 5.4% |
| Op Mgn LTM | 18.5% |
| Op Mgn 3Y Avg | 18.6% |
| QoQ Delta Op Mgn LTM | 1.0% |
| CFO/Rev LTM | 20.6% |
| CFO/Rev 3Y Avg | 20.6% |
| FCF/Rev LTM | 17.2% |
| FCF/Rev 3Y Avg | 15.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 62.5 |
| P/S | 3.7 |
| P/Op Inc | 18.7 |
| P/EBIT | 16.7 |
| P/E | 23.4 |
| P/CFO | 15.8 |
| Total Yield | 4.5% |
| Dividend Yield | 1.0% |
| FCF Yield 3Y Avg | 4.1% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 2.4% |
| 3M Rtn | 0.6% |
| 6M Rtn | -11.0% |
| 12M Rtn | -0.3% |
| 3Y Rtn | 9.4% |
| 1M Excs Rtn | -6.0% |
| 3M Excs Rtn | -3.2% |
| 6M Excs Rtn | -16.4% |
| 12M Excs Rtn | -36.9% |
| 3Y Excs Rtn | -58.2% |
Price Behavior
Price Behavior
| Market Price | $23.76 | |
| Market Cap ($ Bil) | 1.4 | |
| First Trading Date | 05/29/2008 | |
| Distance from 52W High | -36.4% | |
| 50 Days | 200 Days | |
| DMA Price | $23.53 | $27.52 |
| DMA Trend | down | down |
| Distance from DMA | 1.0% | -13.7% |
| 3M | 1YR | |
| Volatility | 55.2% | 52.8% |
| Downside Capture | 0.19 | 0.79 |
| Upside Capture | 72.91 | 81.36 |
| Correlation (SPY) | 24.2% | 41.4% |
ENOV Betas & Captures as of 3/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.39 | 1.32 | 1.37 | 1.61 | 1.39 | 1.30 |
| Up Beta | 0.79 | 1.75 | 3.38 | 3.35 | 1.60 | 1.57 |
| Down Beta | 0.12 | 1.89 | 1.74 | 1.95 | 1.34 | 1.34 |
| Up Capture | 246% | 159% | 57% | 72% | 74% | 57% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 11 | 22 | 29 | 59 | 113 | 340 |
| Down Capture | 174% | 76% | 108% | 128% | 131% | 107% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 11 | 20 | 34 | 65 | 134 | 405 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ENOV | |
|---|---|---|---|---|
| ENOV | -25.3% | 52.8% | -0.37 | - |
| Sector ETF (XLV) | 12.0% | 15.9% | 0.52 | 41.0% |
| Equity (SPY) | 26.7% | 12.5% | 1.77 | 43.7% |
| Gold (GLD) | 38.9% | 27.4% | 1.19 | 6.1% |
| Commodities (DBC) | 23.5% | 16.2% | 1.32 | 2.3% |
| Real Estate (VNQ) | 15.6% | 13.6% | 0.82 | 40.9% |
| Bitcoin (BTCUSD) | -12.8% | 42.6% | -0.21 | 19.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ENOV | |
|---|---|---|---|---|
| ENOV | -11.5% | 51.9% | -0.09 | - |
| Sector ETF (XLV) | 5.6% | 14.6% | 0.20 | 32.9% |
| Equity (SPY) | 10.5% | 17.1% | 0.48 | 37.7% |
| Gold (GLD) | 21.5% | 17.8% | 0.99 | 6.0% |
| Commodities (DBC) | 10.7% | 18.8% | 0.47 | 8.4% |
| Real Estate (VNQ) | 3.6% | 18.8% | 0.09 | 34.8% |
| Bitcoin (BTCUSD) | 3.8% | 56.4% | 0.29 | 15.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ENOV | |
|---|---|---|---|---|
| ENOV | -2.6% | 49.1% | 0.12 | - |
| Sector ETF (XLV) | 9.5% | 16.5% | 0.46 | 42.8% |
| Equity (SPY) | 13.8% | 17.9% | 0.66 | 51.0% |
| Gold (GLD) | 13.9% | 15.9% | 0.73 | 2.3% |
| Commodities (DBC) | 8.1% | 17.6% | 0.38 | 22.9% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 43.5% |
| Bitcoin (BTCUSD) | 68.1% | 66.9% | 1.07 | 12.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/26/2026 | 13.9% | 15.5% | 4.7% |
| 11/6/2025 | -9.7% | -0.8% | -15.0% |
| 8/7/2025 | 10.7% | 14.9% | 24.7% |
| 5/8/2025 | -3.4% | 5.8% | -7.2% |
| 2/26/2025 | -5.0% | -13.0% | -6.9% |
| 11/6/2024 | 8.3% | 8.3% | 10.6% |
| 8/7/2024 | -3.4% | 3.0% | 2.7% |
| 5/2/2024 | -5.9% | -8.5% | -9.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 11 | 10 |
| # Negative | 13 | 11 | 12 |
| Median Positive | 5.6% | 6.4% | 8.2% |
| Median Negative | -3.9% | -6.9% | -8.2% |
| Max Positive | 13.9% | 20.6% | 30.8% |
| Max Negative | -9.7% | -13.0% | -19.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/22/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 2/26/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 2.31 Bil | 2.34 Bil | 2.37 Bil | 3.8% | Higher New | Guidance: 2.25 Bil for 2025 | |
| 2026 Organic Revenue Growth | 4.0% | 5.0% | 6.0% | ||||
| 2026 Adjusted EBITDA | 425.00 Mil | 430.00 Mil | 435.00 Mil | 7.5% | Higher New | Guidance: 400.00 Mil for 2025 | |
| 2026 Adjusted EPS | 3.52 | 3.62 | 3.73 | 14.2% | Higher New | Guidance: 3.17 for 2025 | |
Prior: Q3 2025 Earnings Reported 11/6/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | 2.24 Bil | 2.25 Bil | 2.27 Bil | -0.2% | Lowered | Guidance: 2.26 Bil for 2025 | |
| 2025 Adjusted EBITDA | 395.00 Mil | 400.00 Mil | 405.00 Mil | 0.8% | Raised | Guidance: 397.00 Mil for 2025 | |
| 2025 Adjusted EPS | 3.1 | 3.17 | 3.25 | 1.6% | Raised | Guidance: 3.12 for 2025 | |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.